Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT02884037
·
clinicaltrials.gov ↗
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG:
Rifaximin group 1
Sponsor
Mansoura University